Brain Atrophy as an Outcome of Disease-Modifying Therapy for Remitting-Relapsing Multiple Sclerosis

Introduction. Currently, clinical trials of DMTs strive to determine their effect on neuroinflammation and neurodegeneration. We aimed to determine the impact of currently used DMTs on brain atrophy and disability in RRMS. The main goal of this review is to evaluate the neuroprotective potential of...

Full description

Saved in:

Bibliographic Details
Published in:	Multiple sclerosis international Vol. 2023; pp. 1 - 11
Main Authors:	Chylińska, Magdalena, Komendziński, Jakub, Wyszomirski, Adam, Karaszewski, Bartosz
Format:	Journal Article
Language:	English
Published:	New York Hindawi 31.08.2023 John Wiley & Sons, Inc
Subjects:	Atrophy Automation Care and treatment Clinical trials Diagnostic imaging Inflammation Information processing Magnetic resonance imaging Methods Monoclonal antibodies Multiple sclerosis Nervous system Neurodegeneration Processing speed Review Shrinkage
ISSN:	2090-2654, 2090-2662
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!